Sonoma Pharmaceuticals, Inc.

SNOA • Drug Manufacturers - Specialty & Generic

$1.32

▲ +0.00 (+0.38%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$5.10M

Crecimiento

-16.3%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.27Liquidez saludable · 2.5Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.33

Change0.38%

Shares Out3.85M

Market Cap$5.10M

Enterprise Value$496.95K

52W Range0.85 - 6.92

Beta1.30

P/E-2.25

P/S0.23

P/B0.77

P/FCF-3.16

EV/Sales0.02

Price$1.33

Change0.38%

Shares Out3.85M

Market Cap$5.10M

Enterprise Value$496.95K

52W Range0.85 - 6.92

Beta1.30

P/E-2.25

P/S0.23

P/B0.77

P/FCF-3.16

EV/Sales0.02

EV/EBITDA-0.22

EV/FCF-0.31

Earnings Yield-44.43%

FCF Yield-31.63%

Dividend Yield0.00%

Gross Margin37.97%

Oper. Margin-12.60%

Profit Margin-16.26%

Debt/Eq0.27

Current Ratio2.50

Quick Ratio1.75

Revenue 5Y-16.30%

Volume36.21K

Avg Volume222.22K

EPS Surprise-0.06

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

94/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.27Liquidez saludable · 2.5Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

SNOA

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

75/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 1/25/2007

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 0.77

Deuda / Patrimonio i: 0.27

Margen operativo: -12.60%

Margen neto: -16.26%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.27

Ratio corriente: 2.50

Ratio rápido: 1.75

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Dal Poggetto John

Transacción: 07/09/2026

COMPRA

Cambio

+7,500

Precio

Not reported

Presentación

07/09/2026

Tipo

COMPRA

DVONCH JEROME J

Transacción: 07/09/2026

COMPRA

Cambio

+10,000

Precio

Not reported

Presentación

07/09/2026

Tipo

COMPRA

Jacoby Vanessa

Transacción: 07/09/2026

COMPRA

Cambio

+10,000

Precio

$1.26

Presentación

07/09/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Dal Poggetto John	COMPRA	+7,500	Not reported	07/09/2026	07/09/2026
DVONCH JEROME J	COMPRA	+10,000	Not reported	07/09/2026	07/09/2026
Jacoby Vanessa	COMPRA	+10,000	$1.26	07/09/2026	07/09/2026
MCLAUGHLIN JOHN	COMPRA	+10,000	$1.26	07/09/2026	07/09/2026
Trombly Amy Moss	COMPRA	+10,000	Not reported	07/09/2026	07/09/2026
Weigerstorfer Philippe	COMPRA	+10,000	$1.26	07/09/2026	07/09/2026
Jacoby Vanessa	OTRO	+10,000	$10000.00	01/28/2027	02/09/2026
Birnbaum Jay E	COMPRA	+10,000	$3.68	01/02/2026	01/02/2026
Dal Poggetto John	COMPRA	+5,000	Not reported	01/02/2026	01/02/2026
DVONCH JEROME J	COMPRA	+5,000	Not reported	01/02/2026	01/02/2026
MCLAUGHLIN JOHN	COMPRA	+10,000	$3.68	01/02/2026	01/02/2026
Trombly Amy Moss	COMPRA	+10,000	Not reported	01/02/2026	01/02/2026
Weigerstorfer Philippe	COMPRA	+10,000	$3.68	01/02/2026	01/02/2026
Trombly Amy Moss	COMPRA	+13,500	Not reported	06/19/2025	06/20/2025
DVONCH JEROME J	COMPRA	+13,500	Not reported	06/19/2025	06/20/2025
Dal Poggetto John	COMPRA	+10,000	Not reported	06/19/2025	06/20/2025
Thornton Bruce	COMPRA	+13,500	Not reported	06/19/2025	06/20/2025
Dal Poggetto John	COMPRA	+7,500	Not reported	01/02/2025	01/03/2025
DVONCH JEROME J	COMPRA	+10,000	Not reported	01/02/2025	01/03/2025
Weigerstorfer Philippe	COMPRA	+7,500	$2.68	01/02/2025	01/03/2025

Sobre la compañía

Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.

Fuente - Link

Competidores

BFRI CPHI EVOK FLGC MYNZ NBY QNRX RADX TCRT YCBD

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA clearance and new global distributors support continued commercial growth BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2026. "Our first quarter results demonstrate that Sonoma has reached an important inflection point," said Amy Trombly, CEO of Sonoma.

Accesswire

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) on Thursday posted a first-quarter loss of 9 cents per share compared to a loss of 76 cents a year ago.

Benzinga

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn® Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configurations. Under this new clearance, Microdacyn Wound Irrigation Solution can be used under the supervision of a healthcare professional for cleansing, irrigating, moistening, debridement and removal of foreign material including microorganisms from exudating and/or dirty wounds, acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post‑surgical wounds, first and partial thickness second degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted and donor sites, and exit sites, and for moistening and lubricating absorbent wound dressings.

Accesswire

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025 United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025 Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025 EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025 BOULDER, CO / ACCESS Newswire / June 16, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2026 and the fourth quarter ended March 31, 2026. "Fiscal 2026 was a year of significant progress for Sonoma," remarked Amy Trombly, CEO of Sonoma.

Accesswire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-02-10	-0.29	-0.35	-0.06
2025-11-04	-0.31	-0.13	0.18
2025-08-07	-0.51	-0.37	0.14
2025-06-17	-0.73	-0.15	0.58
2025-02-05	-0.8	-0.59	0.21
2024-11-07	-1	-0.59	0.41
2024-08-08	-0.06	-1.4	-1.34
2024-06-17	-3.40818	-1.4	2.00818
2024-02-08	-0.21	-1.2	-0.99
2023-11-13	-0.24	-4	-3.76
2023-08-10	-2.4	-5.8	-3.4
2019-11-14	-1.18	-18.2	-17.02